LSI USA 2026 Debrief: What Investors Expect Now from MedTech Companies
LSI USA continues to be one of the most efficient signals for where medtech is headed, including who is getting funded, what investors care about, and where companies are getting stuck.
This year’s conversations reinforced a shift that’s been building: capital is still available, but investor expectations are higher and founders must show stronger evidence, sharper strategy, and clear execution plans.
Here’s a grounded breakdown of what stood out and what it means for teams trying to move from concept to commercialization in 2026.
High-Value Conversations Drive Outcomes
LSI USA delivered what it’s known for: high-quality, targeted interactions. The boutique structure created space for meaningful conversations rather than surface-level networking.
Two things stood out:
Strong attendance from both investors and active operators
High conversion of conversations into real connections
This meant less “pitch theater” and more actionable dialogue, often happening in informal settings. Some of the most valuable conversations didn’t happen in scheduled meetings, but in line for coffee or meals.
Takeaway: Founders should treat every interaction as high stakes. The environment rewards preparation and clarity, not volume.
Funding Requires More Than Proof of Concept
The biggest shift in investor mindset is straightforward: there is capital, but not for ideas alone.
Investors consistently signaled:
Clinical data is now a baseline expectation, not a differentiator
Later-stage companies are more attractive than early-stage concepts because they carry less risk
Seed and bridge rounds are harder to secure and require stronger justification
Even when early-stage companies attract interest, they must show a credible path to clinical validation, not just technical feasibility.
Takeaway: The “proof-of-concept → funding” model is no longer reliable. Teams must plan for longer pre-funding timelines, more capital required before raising, and earlier integration of clinical strategy.
Clinical Data Drives Decisions
Across panels and conversations, one theme dominated: clinical evidence now acts as the primary signal for investment.
Investors want:
Data tied to clear endpoints
Evidence aligned with regulatory and reimbursement strategy
Signals of real-world adoption potential
They’re asking for the right evidence at the right time. Teams don’t always need large, randomized controlled trials. Intentional studies with meaningful endpoints can generate the evidence investors expect.
Strong teams define what “good enough” evidence looks like early. They build clinical plans that reach that milestone efficiently and expand from there.
For companies targeting U.S. commercialization, this approach supports more effective engagement with the FDA and reduces downstream risk.
Takeaway: Build a clinical plan early. Use right-sized trial design to generate evidence that supports both regulatory and funding milestones.
Regulatory Strategy Shapes Outcomes
Founders asked one question often: “How is the FDA responding to recent disruption?”
The answer, reflected across conversations:
Frustration exists due to ongoing uncertainty and workforce disruption
Teams are working through it, but expectations are less predictable
Programs like Breakthrough Device feel less impactful than before
Many founder frustrations traced back to poor regulatory strategy, not just agency behavior.
Common issues include:
Delayed engagement with the FDA
Misalignment between testing, claims, and pathway
Overconfidence in pathway assumptions (especially De Novo concerns)
For example, misconceptions persist that De Novo is a negative outcome. In reality, it often provides a viable and efficient path for novel devices when properly positioned.
Takeaway: Regulatory is no longer a compliance function. It’s a strategic lever that directly impacts funding, timelines, and risk.
Integration Wins: Regulatory, Clinical, and Market Access
One of the clearest signals from investors and strategics: Siloed strategies fail. Integrated strategies win.
Investors are evaluating:
Clinical plans tied to reimbursement pathways
Regulatory timelines aligned with commercialization milestones
Market access strategies that drive adoption
Teams that align these functions early move faster and de-risk their programs more effectively.
Takeaway: Align regulatory, clinical, and commercial strategy from the start.
AI Remains Active but Not Dominant
AI and digital health appeared across discussions, but with nuance:
Interest remains high
Capital isn’t concentrated solely on AI
Revenue models remain unclear for many solutions
Regulatory clarity continues to improve, but use cases evolve faster than guidance, creating a familiar gap between innovation and oversight.
Takeaway: Position AI within a broader value story that includes evidence, adoption, and revenue clarity.
What Separates Teams That Move from Those That Stall
High-performing teams shared a few consistent traits:
A focused, compelling story
Evidence that strengthens over time
Disciplined capital allocation
Teams that struggle often:
Spread resources across too many priorities
Delay regulatory and clinical planning
Underestimate development timelines
Takeaway: Focus on the few actions that create immediate value.
Tactical Advice for Founders Coming Out of LSI
If you attended LSI USA or plan to next year, execution matters:
Research attendees in advance.
Prioritize high-value meetings.
Expect meaningful conversations to happen outside formal sessions.
Be persistent but targeted in outreach.
Define what “good enough” looks like for your next milestone.
Plan the work, then execute against that plan.
Why It Matters and How NMCG Helps
The current medtech environment isn’t constrained by capital—it’s constrained by execution quality.
Investors are funding:
Companies with credible clinical pathways
Teams with integrated regulatory and commercial strategies
Programs that reduce uncertainty early
That’s where NMCG operates. As a boutique CRO and regulatory partner NMCG helps teams:
Design right-sized clinical strategies aligned with funding expectations
Build regulatory pathways that reduce risk
Integrate clinical, regulatory, and market access into a single execution plan
Teams that engage early build stronger programs, avoid delays, and improve their position with investors and regulators.
